Talphera Cuts Costs and Speeds Trial

Talphera(NASDAQ:TLPH) reported second quarter 2025 results on August 14, 2025, highlighting accelerated clinical trial enrollment and a reduction in annual cash operating expense guidance to $16 million–$17 million for 2025. The company ended the quarter with $6.8 million in cash and reaffirmed its plan to complete the pivotal Niyad (nafamostat) study by year-end 2025. The following insights detail the operational turnaround, financing structure, and market entry strategy discussed on the call.After appointing Dr. Shakil Aslam as Chief Medical Officer, Talphera reduced the nephro CRRT (continuous renal replacement therapy) trial size to 70 patients and implemented new site and investigator selection criteria. Over the last six weeks, more than 90% of enrolled patients have come from three new target profile sites, a significant improvement over legacy site performance.This operational shift demonstrates management’s ability to identify and address bottlenecks, increasing confidence in timely trial completion and reducing the risk of enrollment-driven delays.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool